Sterling Capital Management’s NovoCure NVCR Stock Holding History

Sterling Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.58K	Sell	500 -160	-24%	-$2.42K	﹤0.01%	2382
2026 Q1	$7.19K	Sell	660 -15	-2%	-$187	﹤0.01%	2556
2025 Q4	$8.73K	Buy	675 +429	+174%	+$5.51K	﹤0.01%	2675
2025 Q3	$3.18K	Hold	246	–	–	﹤0.01%	2900
2025 Q2	$4.38K	Buy	246 +135	+122%	+$2.35K	﹤0.01%	2581
2025 Q1	$1.98K	Buy	111 +4	+4%	+$91	﹤0.01%	2613
2024 Q4	$3.19K	Sell	107 -3	-3%	-$63	﹤0.01%	2629
2024 Q3	$1.72K	Buy	+110	New	+$2K	﹤0.01%	2252

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Sterling Capital Management's NVCR Position: Q2 2026 in Review

Sterling Capital Management reduced its NovoCure (NVCR) stake by 24% in Q2 2026, selling an estimated $2.42K and leaving 500 shares worth $7.58K. The position accounts for ﹤0.01% of the portfolio, ranked #2382.

Sterling Capital Management first reported a position in NVCR in Q3 2024 and has held it in 8 quarters since. The position peaked at $8.73K in Q4 2025. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Sterling Capital Management held 500 shares of NovoCure worth $7.58K as of Q2 2026.
Sterling Capital Management sold 160 NovoCure shares in Q2 2026, an estimated $2.42K.
NovoCure made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2382 holding.
Sterling Capital Management first reported a position in NovoCure in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's NovoCure position peaked at $8.73K in Q4 2025.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.